Peter DeMuth

Company: Elicio Therapeutics

Job title: Vice President - Research

Seminars:

Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease 4:00 pm

Dissecting what exactly is lacking in the current models and bridging the translation gap Exploring how we can design/strategize/use the right models to really represent what we want Exploring what constitutes sensitivity Using models to predict the severe side effects seen in humans Understanding what the best setting is to do efficacy/new target discovery for…Read more

day: Day One